Imovax Polio Mechanism of Action

Pharmacotherapeutic group: Vaccine against poliomyelitis. ATC code: J07BF03.
Pharmacology: Pharmacodynamics: The vaccine is prepared from poliovirus types 1, 2 and 3 cultured on Vero cells, purified and inactivated by formaldehyde.
One month after primary vaccination starting at 2 months of age and using 3 doses of Imovax Polio 1 to 2 months apart, seroprotection rates were 99% to 100% for types 1 and 3 polioviruses, and 97% to 100% for type 2 poliovirus.
For infants, the booster dose (4th dose) led to a large increase in titres with seroprotection rates of 97.5% to 100% for the three types of polioviruses.
Children primed with IPV during infancy and boosted in the second year of life maintain high levels (≥ 80%) of seroprotective antibodies at 4-6 years of age, and produce a strong anamnestic response (97-100% seroprotection) following a second IPV booster.
In primed adults, a booster injection is followed by an anamnestic response.
For the most part, these data comes from studies done with combined vaccines containing poliomyelitis vaccine.
Immunity lasts for at least 5 years after the 4th injection.
Pharmacokinetics: Not applicable.
Toxicology: Preclinical safety data: Non-clinical data revealed no special hazard for humans based on conventional acute toxicity, repeat dose toxicity and local tolerance studies.